SEPI: IND Submissions 101
Dec 05, 2013 (Thu) | 8:30 AM -9:45 AM
LI Ka Shing Center, LK101 : Stanford, CA
An Investigational New Drug Application (IND) is a request for authorization from the FDA to administer an investigational drug or biological product to humans, exempting the drug/biologic from premarketing approval requirements so that experimental clinical trials may be conducted. In this workshop, a panel will provide the basics of IND submissions and lead a discussion following the presentation. Speakers will cover Stanford resources for IND submissions including SPARK, CCTO, and Spectrum and share lessons learned from investigator-initiated IND studies.
Department: Spectrum: Center for Translational and Clinical Research and Education
Contact: Jessica P. Meyer | 650-498-6140 | email@example.com